Mettler-Toledo AI Stock Analysis
Want to see MTD full AI Analyst Report?
Mettler-Toledo (MTD) AI Stock Analysis
Mettler-Toledo
(NYSE:MTD)
MTD scores well due to strong profitability and free-cash-flow generation, reinforced by a bullish technical backdrop and a notably positive earnings outlook (raised 2026 outlook and solid 2027 EPS growth guidance). The score is held back primarily by balance-sheet risk (thin/volatile equity and meaningful debt) and a premium valuation (P/E ~36).
Mettler-Toledo Key Performance Indicators (KPIs)
Revenue By SegmentAnalyzes income from different business segments, highlighting which areas drive growth and profitability, and where the company might be vulnerable or have expansion opportunities.
Industrial is clearly the growth engine — recent quarters show accelerating, consistent gains that drove the company’s top‑line beat — while Laboratory has recovered from earlier softness and now supplies a large, stable revenue base. Retail is volatile and too small to offset swings in the bigger segments. Management’s call confirms this mix: acquisitions are a minor sales kicker and U.S. import tariffs are the principal margin risk that could mute EPS upside even if sales continue to improve into 2026.
Mettler-Toledo (MTD) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $34.59B
- Dividend Yield
- ―
- Average Volume (3M)
- 200.00K
- Price to Earnings (P/E)
- 37.6
- Beta (1Y)
- 0.94
- Revenue Growth
- 6.51%
- EPS Growth
- 15.03%
- Country
- US
- Employees
- 16,600
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Mettler-Toledo Business Overview & Revenue Model
Company Description
Mettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services. The company's operations are strategically organized across five geographical divisions: its domes...
How the Company Makes Money
Mettler-Toledo primarily makes money by selling precision measurement and inspection equipment and by providing recurring services that support those installed instruments. Key revenue streams include: (1) Instrument and system sales: revenue from th...
Mettler-Toledo Earnings Call Summary
The call was strongly positive overall. The company reported broad-based 6% organic sales growth, 13% adjusted EPS growth, improved margins, strong momentum in China and emerging markets, a raised 2026 outlook, and 10% to 12% expected adjusted EPS growth for 2027. Management also highlighted improving laboratory demand, automation and digitalization opportunities, strategic investments, and growing onshoring activity. The main cautions were subdued European conditions, food retail and near-term product-inspection softness, higher material and transportation costs, tariff and foreign-exchange uncertainty, difficult China comparisons, and the extended timing of onshoring benefits. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the fourth quarter of 2026, local currency sales growth is forecast at approximately 5%, adjusted EPS is forecast to be in the range of $14.84 to $15.04, representing a growth rate of 11% to 13%, and pricing is expected to be in that 2.5 percent range; for full year 2026, local currency sales growth is forecast at approximately 5%, reflecting organic growth of 4%, and adjusted EPS is forecast to be in the range of $47.70 to $47.90, representing a growth rate of 12%. For 2027, local currency sales are expected to increase approximately 5%, adjusted EPS is forecast to be in the range of $52.50 to $53.50, representing a growth rate of 10% to 12%, foreign exchange is estimated to be a 1% headwind to sales growth and neutral to EPS, price is expected to be just over 2% and volume in the 3% ish kind of a range, lab is guided mid to high single digit, core industrial mid-single-digit, product inspection low to mid single digit, food retailing low single digit, The Americas mid to high single digit, Europe low single digit, and China mid single digit; total amortization is expected to be approximately $76 million, purchased intangible amortization approximately $27 million on a pretax basis for approximately $1 per share, interest expense $68 million, other income approximately $22 million, the tax rate before discrete items 18%, free cash flow approximately $950 million, representing 8% growth on a per share basis, and share repurchases $950 million.
Mettler-Toledo Financial Statement Overview
Summary
Strong profitability and cash generation (TTM net margin ~21%–22%, TTM FCF ~$871M with ~0.88x net-income conversion) support a solid score, but it is materially constrained by balance-sheet risk: meaningful leverage (~$2.0–$2.3B debt) and historically thin/negative equity, leaving limited cushion if operating conditions weaken. A watch item is the TTM step-down in EBIT margin (~21%) versus prior annual levels (~27%–29%).
Income Statement
86Very PositiveBalance Sheet
48NeutralCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.20B | 4.03B | 3.87B | 3.79B | 3.92B | 3.72B |
| Gross Profit | 2.48B | 2.39B | 2.25B | 2.17B | 2.24B | 2.11B |
| EBITDA | 1.33B | 1.24B | 1.25B | 1.20B | 1.24B | 1.10B |
| Net Income | 934.07M | 869.19M | 863.14M | 788.78M | 872.50M | 768.99M |
Balance Sheet | ||||||
| Total Assets | 3.70B | 3.71B | 3.24B | 3.36B | 3.49B | 3.33B |
| Cash, Cash Equivalents and Short-Term Investments | 52.24M | 66.89M | 59.36M | 69.81M | 95.97M | 98.56M |
| Total Debt | 2.02B | 2.34B | 2.13B | 2.20B | 2.13B | 1.80B |
| Total Liabilities | 3.62B | 3.74B | 3.37B | 3.51B | 3.47B | 3.16B |
| Stockholders Equity | 77.66M | -23.64M | -126.89M | -149.94M | 24.79M | 171.42M |
Cash Flow | ||||||
| Free Cash Flow | 870.57M | 848.65M | 864.45M | 860.55M | 737.83M | 801.25M |
| Operating Cash Flow | 984.37M | 955.77M | 968.35M | 965.87M | 859.07M | 908.83M |
| Investing Cash Flow | -84.27M | -193.87M | -119.46M | -131.69M | -139.40M | -314.11M |
| Financing Cash Flow | -921.82M | -755.17M | -855.98M | -859.59M | -716.04M | -590.55M |
Mettler-Toledo Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTD, the sentiment is Positive. The current price of 1738.91 is above the 20-day moving average (MA) of 1698.63, above the 50-day MA of 1560.60, and above the 200-day MA of 1352.19, indicating a bullish trend. The MACD of 48.92 indicates Positive momentum. The RSI at 64.13 is Neutral, neither overbought nor oversold. The STOCH value of 53.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MTD.
Mettler-Toledo Risk Analysis
Mettler-Toledo disclosed 29 risk factors in its most recent earnings report. Mettler-Toledo reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksMettler-Toledo Peers Comparison
Overall Rating
A78Outperform
TMO76.9Outperform
ILMN75Outperform
MTD75Outperform
DHR73Outperform
WAT59Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | $49.04B | 34.18 | 20.47% | 0.59% | 8.60% | 19.07% | |
| 77Outperform | $259.44B | 36.87 | 13.31% | 0.26% | 8.27% | 9.59% | |
| 75Outperform | $31.30B | 35.15 | 31.45% | ― | 6.00% | 31.48% | |
| 75Outperform | $34.59B | 37.59 | 9999.00% | ― | 6.51% | 15.03% | |
| 73Outperform | $163.94B | 38.08 | 8.18% | 0.65% | 5.52% | 25.53% | |
| 59Neutral | $45.24B | 195.85 | 0.81% | ― | 80.68% | -78.49% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MTD | Mettler-toledo International | 1738.91 | 349.95 | 25.20% | |
| A | Agilent Technologies | 173.96 | 30.52 | 21.27% | |
| DHR | Danaher Corporation | 233.02 | 14.20 | 6.49% | |
| ILMN | Illumina | 207.01 | 86.93 | 72.39% | |
| TMO | Thermo Fisher Scientific | 700.22 | 135.05 | 23.89% | |
| WAT | Waters Corp | 460.25 | 82.27 | 21.77% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
